COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
08/11/2024
Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024
08/11/2024
Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
08/11/2024
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024
08/11/2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : [...]
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences
08/11/2024
8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of T he NGAL Test to Clinicians at Major Healthcare Conferences COPENHAGEN, DENMARK and BOSTON [...]
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
08/11/2024
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy. Predictive biomarkers correlated [...]
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
08/11/2024
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where [...]
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
08/11/2024
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the [...]
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
08/11/2024
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars highlighted [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08/11/2024
Bagsværd, Denmark, 8 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Director/PDMR Shareholding
08/11/2024
DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support [...]
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
08/11/2024
Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in monotherapy (KVA12123 [...]
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
08/11/2024
First randomized placebo-controlled trial in NTM abscessus Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms Microbiologic endpoints showed higher conversion to [...]
AVITA Medical to Host Investor Webinar Briefing
08/11/2024
VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
08/11/2024
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with [...]
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
08/11/2024
Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half [...]
Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference
08/11/2024
LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Vera Therapeutics to Participate at Upcoming Investor Conferences
08/11/2024
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
08/11/2024
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill [...]

Pages